within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AG07_Sorbitol;

model Sorbitol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 5.833333333333333e-06,
    adminDuration = 600,
    adminMass = 20000 / 1000000,
    adminCount = 1,
    Vd = 0.0006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Sorbitol</td></tr><tr><td>ATC code:</td><td>A06AG07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>20000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Sorbitol is a sugar alcohol used primarily as a laxative to treat constipation and to clear the bowel before diagnostic tests. It is also used as a sweetener in various pharmaceutical and food products. Sorbitol is approved and used in current medical practice, mainly for its osmotic laxative effects.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults after oral administration, as direct PK data on sorbitol in the published literature are not available.</p><h4>References</h4><ol><li><p>Yang, D, et al., &amp; Chen, J (2024). Bioequivalence Study of Epalrestat for Healthy Chinese Subjects. <i>Clinical pharmacology in drug development</i> 13(5) 485–490. DOI:<a href=\"https://doi.org/10.1002/cpdd.1347\">10.1002/cpdd.1347</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37971280/\">https://pubmed.ncbi.nlm.nih.gov/37971280</a></p></li><li><p>Jain, NK, et al., &amp; Pitchumoni, CS (1987). Sorbitol intolerance in adults. Prevalence and pathogenesis on two continents. <i>Journal of clinical gastroenterology</i> 9(3) 317–319. DOI:<a href=\"https://doi.org/10.1097/00004836-198706000-00015\">10.1097/00004836-198706000-00015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3611685/\">https://pubmed.ncbi.nlm.nih.gov/3611685</a></p></li><li><p>Matsui, K, et al., &amp; Yokota, S (2021). Potential pharmacokinetic interaction between orally administered drug and osmotically active excipients in pediatric polypharmacy. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 165 105934–None. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2021.105934\">10.1016/j.ejps.2021.105934</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34256099/\">https://pubmed.ncbi.nlm.nih.gov/34256099</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A06AG07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Sorbitol;
